← Back to graph
Supplement

Lactobacillus crispatus CTV-05

Selected indexed studies

  • Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial. (Lancet Microbe, 2025) [PMID:40194532]
  • Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease. (Sex Transm Dis, 2024) [PMID:38733973]
  • Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. (N Engl J Med, 2020) [PMID:32402161]

_Worker-drafted node — pending editorial review._

Connections

Lactobacillus crispatus CTV-05 helps

Sources

Local graph